Back HIV Treatment

HIV Treatment

Gilead Requests FDA Approval of Tenofovir Alafenamide Single-Tablet Regimen

Gilead Sciences has requested U.S. Food and Drug Administration approval of a 1-pill-once-daily coformulation containing tenofovir alafenamide (TAF) -- a new formulation that is easier on the kidneys and bones -- plus emtricitabine and Jansen's NNRTI rilpivirine (Edurant), the company announced this week.

alt

Read more:

New British Guidelines Recommend Treatment for Everyone with HIV

Everyone with HIV who is prepared to take antiretroviral treatment should receive it, regardless of CD4 cell count, new draft British HIV Association (BHIVA) treatment guidelines recommend. The new draft guidelines, published for consultation this week, say that anyone living with HIV who understands the commitment of antiretroviral therapy and is ready to start should receive treatment. The change -- from a recommendation to start treatment before the CD4 cell count falls below 350 cells/mm3 to treatment for all -- follows the results of the START trial, a keenly awaited international study of when to start treatment.

alt

Read more:

First START Results Show Early HIV Treatments Reduces Risk of Illness and Death

Long-awaited interim findings from the START trial have shown that people with HIV who were randomly assigned to start antiretroviral therapy (ART) while their CD4 count was above 500 cells/mm3 had a 53% lower risk of AIDS-related and non-AIDS illnesses and deaths compared to those who waited until their count fell below 350 cells/mm3, according to an announcement today from the National Institute of Allergy and Infectious Diseases.

alt

Read more:

START Study Confirms Benefits of Early HIV Treatment

Long-awaited results from the START study show that people with HIV who start antiretroviral therapy (ART) soon after diagnosis, while their CD4 T-cell count is still high, have a lower risk of illness and death than those who wait, according to a May 27 announcement from the National Institute of Allergy and Infectious Diseases.

alt

Read more:

BHIVA 2015: Many People with HIV Willing to Take Part in Cure Research Despite its Risks

There is a strong interest among people living with HIV in research towards an HIV cure, with many potential participants willing to consider antiretroviral treatment interruption. Respondents to a survey presented at the British HIV Association (BHIVA) conference this week in Brighton generally understood that they would be unlikely to benefit personally from cure research. Priorities for a cure were to eliminate health problems and the risk of HIV transmission, rather than necessarily testing HIV-negative.

alt

Read more: